Phase II trial of MGN 1703 in patients with advanced non-small cell lung cancer who have responded to first-line chemotherapy.

Trial Profile

Phase II trial of MGN 1703 in patients with advanced non-small cell lung cancer who have responded to first-line chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IMPACT-2
  • Sponsors Mologen
  • Most Recent Events

    • 10 Oct 2013 Status changed from planning to discontinued. A trial in small cell lung cancer will replace the trial application submitted for the non-small cell lung cancer trial, according to a Mologen media release.
    • 15 Mar 2012 The trial protocol has been amended, according to a Mologen AG media release.
    • 13 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top